Glargine versus NPH insulin: Efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes-The glargine and aspart study (GLASS). A randomised cross-over study

Diabetes Research and Clinical Practice

Volumn 77, Issue 2, 2007, Pages 215-222

  Chatterjee, S ^a   Jarvis Kay, J ^a   Rengarajan, T ^a   Lawrence, I G ^a   McNally, P G ^a   Davies, M J ^a  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

HbA1c; Insulin analogues; Insulin aspart; Insulin glargine; Type 1 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN GLARGINE; ISOPHANE INSULIN;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT CHANGE; WEIGHT GAIN;

ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, ISOPHANE; MALE; MIDDLE AGED;

EID: 34247627840     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2006.11.002     Document Type: Article

References (26)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329 (1993) 977-986
2. Wang P.H., Lau J., and Chalmers T.C. Meta-analysis of effects of intensive blood glucose control on late complications in type 1 diabetes. Lancet 341 (1993) 1306-1309
3. Reichard P., Nilsson B.Y., and Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N. Engl. J. Med. 329 (1993) 304-309
4. Lepore M., Pampanelli S., Fanelli C., Porcellati F., Bartocci L., Di Vicenzo A., et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analogue glargin, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49 (2000) 2142-2148
5. Rosenstock J., Park G., and Zimmerman J. US insulin glargine (HOE901) type 1 diabetes investigator group 2000. Basal insulin glargine (HOE901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 23 (2000) 1137-1142
6. Pieber T.R., Eugene-Jolchine I., Derobert E., et al. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care 23 (2000) 157-162
7. Ratner R.E., Hirsch I.B., Neifing J.L., Garg S.K., Mecca T.E., and Wilson C.A. Less hypoglycaemia with insulin glargine in intensive insulin therapy for type 1 diabetes. US study group of insulin glargine in type 1 diabetes. Diabetes Care 23 (2000) 639-643
8. Schoenle E. Insulin glargine (HOE901) lowers fasting blood glucose in children with type 1 diabetes mellitus without increasing the risk of hypoglycaemia (abstract). Diabetologia 42 Suppl 1 (1999) A235
9. Rossetti P., Pampanelli S., Fanelli C., et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime. Diabetes Care 26 (2003) 1490-1496
10. Porcellati F., Rossetti P., Pampanelli S., Fanelli C.G., Torlone E., Scionti L., et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with type 1 diabetes mellitus given meal-time Lispro insulin. Diabet. Med. 21 (2004) 1213-1220
11. Hamann A., Matthael S., Rosak C., et al. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care 26 (2003) 1738-1744
12. Murphy N.P., Keane S.Z., Ong K.K., et al. Randomized cross-over trial of insulin glargine plus Lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 26 (2003) 799-804
13. Ashwell S.G., Amiel S.A., Bilous R.W., et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in patients with Type 1 diabetes. Diabet. Med. 23 (2006) 285-292
14. Bradley C., Witthaus E., and Stewart J. Treatment satisfaction and psychological well being in patients with type 1 diabetes, treated with a new long acting insulin, insulin glargine (abstract). Diabetes 47 (1999) 353
15. Garg S.K., Paul J.M., Karsten J.I., Menditto L., and Gottlieb P.A. Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes. Diabetes Technol. Ther. 6 (2004) 589-595
16. Garg S.K., Gottlieb P.A., Hisatomi M.E., D'Souza A., Walker A.J., Izuora K.E., et al. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res. Clin. Pract. 66 (2004) 49-56
17. Bradley C. The Diabetes Treatment Satisfaction Questionnaire: DTSQ. In: Bradley C. (Ed). Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice (1994), Harwood Academic Publishers, Chur, Switzerland 111-132
18. Bradley C., Todd C., Gorton T., Symonds E., Martin A., and Plowright R. The development of an individualised questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL. Qual. Life Res. 8 (1999) 79-91
19. Wang F., Carabino J.M., and Vengara C.M. Insulin glargine: a systematic review of a long-acting insulin analogue. Clin. Ther. 25 (2003) 1541-1577
20. Fahlen M., Eliasson B., and Oden A. Optimization of basal insulin delivery in type 1 diabetes: a retrospective study on the use of continuous subcutaneous insulin infusion and insulin glargine. Diabet. Med. 22 (2004) 382-386
21. Lepore G., Dodesini A.R., Nosari I., and Trevisan R. Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment. Diabetes Care 26 (2003) 1321-1332
22. King A.B., and Armstrong D. A Comparison of basal insulin delivery. Continuous subcutaneous insulin infusion versus glargine. Diabetes Care 26 (2003) 1322
23. National Institute for Clinical Excellence. Guidance on the Use of Continuous Subcutaneous Insulin Infusion in Diabetes. NICE Technology Appraisal Guidance No. 57 (2003), National Institute for Clinical Excellence, London, UK
24. Hoi-Hansen T., Pedersen-Bjergaard U., and Thorsteinsson B. Reproducibility and reliability of hypoglycaemic episodes recorded with Continuous Glucose Monitoring System (CGMS) in daily life. Diabet. Med. 22 (2005) 858-862
25. McGowan K., Thomas W., and Moran A. Spurious reporting of nocturnal hypoglycemia by CGMS in patients with tightly controlled type 1 diabetes. Diabetes Care 25 (2002) 1499-1503
26. DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ 325 (2002) 746